(-)-epigallocatechin 3-gallate multiple interactions ISO RGD:1313286 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SPRY4 mRNA CTD PMID:22079256 (-)-epigallocatechin 3-gallate decreases expression ISO RGD:1313286 6480464 epigallocatechin gallate results in decreased expression of SPRY4 mRNA CTD PMID:35701726 1,2-dimethylhydrazine multiple interactions EXP 6480464 [APC protein affects the susceptibility to 1, 2-Dimethylhydrazine] which results in increased expression of SPRY4 mRNA CTD PMID:27840820 17beta-estradiol increases expression ISO RGD:1313286 6480464 Estradiol results in increased expression of SPRY4 mRNA CTD PMID:23019147 more ... 17beta-estradiol increases expression EXP 6480464 Estradiol results in increased expression of SPRY4 mRNA CTD PMID:32145629 17beta-estradiol multiple interactions ISO RGD:1313286 6480464 [Estradiol co-treated with Progesterone] results in decreased expression of SPRY4 mRNA, [Estradiol co-treated with TGFB1 protein] results in increased expression of SPRY4 mRNA CTD PMID:20660070 , PMID:30165855 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1313286 6480464 Tetrachlorodibenzodioxin results in decreased expression of SPRY4 mRNA CTD PMID:20106945 , PMID:21632981 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of SPRY4 mRNA CTD PMID:33387578 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of SPRY4 mRNA CTD PMID:26232522 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1313287 6480464 Tetrachlorodibenzodioxin affects the expression of SPRY4 mRNA CTD PMID:21570461 3,3',4,4'-tetrachlorobiphenyl multiple interactions ISO RGD:1313287 6480464 3 more ... CTD PMID:19467301 3,3',5,5'-tetrabromobisphenol A increases expression ISO RGD:1313287 6480464 tetrabromobisphenol A results in increased expression of SPRY4 mRNA CTD PMID:25172293 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:1313286 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of SPRY4 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of SPRY4 mRNA CTD PMID:28628672 4,4'-sulfonyldiphenol multiple interactions ISO RGD:1313286 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of SPRY4 mRNA CTD PMID:28628672 4,4'-sulfonyldiphenol affects methylation ISO RGD:1313287 6480464 bis(4-hydroxyphenyl)sulfone affects the methylation of SPRY4 gene CTD PMID:31683443 4,4'-sulfonyldiphenol decreases expression ISO RGD:1313287 6480464 bis(4-hydroxyphenyl)sulfone results in decreased expression of SPRY4 mRNA CTD PMID:33297965 4,4'-sulfonyldiphenol increases expression ISO RGD:1313287 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of SPRY4 mRNA CTD PMID:30951980 4-hydroxyphenyl retinamide increases expression ISO RGD:1313287 6480464 Fenretinide results in increased expression of SPRY4 mRNA CTD PMID:28973697 6-propyl-2-thiouracil affects expression EXP 6480464 Propylthiouracil affects the expression of SPRY4 mRNA CTD PMID:24780913 6-propyl-2-thiouracil increases expression EXP 6480464 Propylthiouracil results in increased expression of SPRY4 mRNA CTD PMID:30047161 acrolein multiple interactions ISO RGD:1313286 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of SPRY4 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in decreased expression of SPRY4 mRNA CTD PMID:32699268 acrylamide decreases expression EXP 6480464 Acrylamide results in decreased expression of SPRY4 mRNA CTD PMID:28959563 aflatoxin B1 increases expression ISO RGD:1313286 6480464 Aflatoxin B1 results in increased expression of SPRY4 mRNA CTD PMID:22100608 aflatoxin B1 increases expression EXP 6480464 Aflatoxin B1 results in increased expression of SPRY4 mRNA CTD PMID:33354967 all-trans-retinoic acid decreases expression ISO RGD:1313286 6480464 Tretinoin results in decreased expression of SPRY4 mRNA CTD PMID:33167477 alpha-pinene multiple interactions ISO RGD:1313286 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of SPRY4 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in decreased expression of SPRY4 mRNA CTD PMID:32699268 amitrole increases expression EXP 6480464 Amitrole results in increased expression of SPRY4 mRNA CTD PMID:30047161 aristolochic acid A increases expression ISO RGD:1313286 6480464 aristolochic acid I results in increased expression of SPRY4 mRNA CTD PMID:33212167 arsenite(3-) increases methylation ISO RGD:1313286 6480464 arsenite results in increased methylation of SPRY4 promoter CTD PMID:23974009 atrazine increases expression EXP 6480464 Atrazine results in increased expression of SPRY4 mRNA CTD PMID:36841081 azathioprine increases expression ISO RGD:1313286 6480464 Azathioprine results in increased expression of SPRY4 mRNA CTD PMID:22623647 benzo[a]pyrene increases expression ISO RGD:1313286 6480464 Benzo(a)pyrene results in increased expression of SPRY4 mRNA CTD PMID:21632981 more ... benzo[a]pyrene increases methylation ISO RGD:1313286 6480464 Benzo(a)pyrene results in increased methylation of SPRY4 5' UTR CTD PMID:27901495 benzo[a]pyrene diol epoxide I decreases expression ISO RGD:1313286 6480464 7 more ... CTD PMID:20382639 benzo[a]pyrene diol epoxide I increases expression ISO RGD:1313286 6480464 7 more ... CTD PMID:26238291 bis(2-chloroethyl) sulfide increases expression ISO RGD:1313287 6480464 Mustard Gas results in increased expression of SPRY4 mRNA CTD PMID:15674844 bis(2-ethylhexyl) phthalate decreases expression ISO RGD:1313287 6480464 Diethylhexyl Phthalate results in decreased expression of SPRY4 mRNA CTD PMID:19850644 bis(2-ethylhexyl) phthalate increases expression ISO RGD:1313286 6480464 Diethylhexyl Phthalate results in increased expression of SPRY4 mRNA CTD PMID:31163220 bis(2-ethylhexyl) phthalate multiple interactions ISO RGD:1313287 6480464 PPARA protein promotes the reaction [Diethylhexyl Phthalate results in decreased expression of SPRY4 mRNA] CTD PMID:19850644 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of SPRY4 mRNA CTD PMID:25181051 , PMID:32145629 bisphenol A increases expression ISO RGD:1313287 6480464 bisphenol A results in increased expression of SPRY4 mRNA CTD PMID:30951980 , PMID:32156529 bisphenol A decreases expression ISO RGD:1313286 6480464 bisphenol A results in decreased expression of SPRY4 mRNA CTD PMID:29275510 bisphenol A decreases expression ISO RGD:1313287 6480464 bisphenol A results in decreased expression of SPRY4 mRNA CTD PMID:25594700 bisphenol F multiple interactions ISO RGD:1313286 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of SPRY4 mRNA CTD PMID:28628672 bisphenol F increases expression ISO RGD:1313287 6480464 bisphenol F results in increased expression of SPRY4 mRNA CTD PMID:30951980 C60 fullerene decreases expression EXP 6480464 fullerene C60 results in decreased expression of SPRY4 mRNA CTD PMID:19167457 caffeine increases phosphorylation ISO RGD:1313286 6480464 Caffeine results in increased phosphorylation of SPRY4 protein CTD PMID:35688186 carbon nanotube increases expression ISO RGD:1313286 6480464 Nanotubes, Carbon analog results in increased expression of SPRY4 mRNA CTD PMID:25102311 carbon nanotube increases expression ISO RGD:1313287 6480464 Nanotubes more ... CTD PMID:25554681 cerium trichloride increases expression ISO RGD:1313287 6480464 cerous chloride results in increased expression of SPRY4 mRNA CTD PMID:23573234 chloroprene decreases expression ISO RGD:1313287 6480464 Chloroprene results in decreased expression of SPRY4 mRNA CTD PMID:23125180 chlorpyrifos increases expression ISO RGD:1313287 6480464 Chlorpyrifos results in increased expression of SPRY4 mRNA CTD PMID:37019170 cisplatin multiple interactions ISO RGD:1313286 6480464 [Cisplatin co-treated with jinfukang] results in decreased expression of SPRY4 mRNA CTD PMID:27392435 clobetasol increases expression ISO RGD:1313287 6480464 Clobetasol results in increased expression of SPRY4 mRNA CTD PMID:27462272 cocaine increases expression EXP 6480464 Cocaine results in increased expression of SPRY4 mRNA CTD PMID:27899881 copper(II) sulfate increases expression ISO RGD:1313286 6480464 Copper Sulfate results in increased expression of SPRY4 mRNA CTD PMID:19549813 crocidolite asbestos increases expression ISO RGD:1313286 6480464 Asbestos, Crocidolite results in increased expression of SPRY4 mRNA CTD PMID:18687144 , PMID:25351596 crocidolite asbestos affects expression ISO RGD:1313286 6480464 Asbestos, Crocidolite affects the expression of SPRY4 mRNA CTD PMID:25757056 Cuprizon increases expression EXP 6480464 Cuprizone results in increased expression of SPRY4 mRNA CTD PMID:27523638 cyclosporin A increases expression ISO RGD:1313286 6480464 Cyclosporine results in increased expression of SPRY4 mRNA CTD PMID:20106945 more ... dexamethasone multiple interactions ISO RGD:1313286 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of SPRY4 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of SPRY4 mRNA CTD PMID:28628672 dibutyl phthalate increases expression EXP 6480464 Dibutyl Phthalate results in increased expression of SPRY4 mRNA CTD PMID:21266533 dibutyl phthalate decreases expression EXP 6480464 Dibutyl Phthalate results in decreased expression of SPRY4 mRNA CTD PMID:31050326 dibutyl phthalate increases expression ISO RGD:1313287 6480464 Dibutyl Phthalate results in increased expression of SPRY4 mRNA CTD PMID:17361019 , PMID:21266533 dichloroacetic acid decreases expression ISO RGD:1313287 6480464 Dichloroacetic Acid results in decreased expression of SPRY4 mRNA CTD PMID:28962523 diclofenac decreases expression ISO RGD:1313287 6480464 Diclofenac results in decreased expression of SPRY4 mRNA CTD PMID:26934552 dicrotophos increases expression ISO RGD:1313286 6480464 dicrotophos results in increased expression of SPRY4 mRNA CTD PMID:28302478 dimethylarsinic acid multiple interactions ISO RGD:1313287 6480464 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPRY4 mRNA CTD PMID:34876320 dioxygen multiple interactions ISO RGD:1313287 6480464 [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of SPRY4 mRNA CTD PMID:30529165 dioxygen multiple interactions EXP 6480464 [Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in increased expression of SPRY4 mRNA CTD PMID:33729688 dorsomorphin multiple interactions ISO RGD:1313286 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin increases expression ISO RGD:1313286 6480464 Doxorubicin results in increased expression of SPRY4 mRNA CTD PMID:30031762 ethanol multiple interactions ISO RGD:1313286 6480464 [Ethanol co-treated with Folic Acid] results in decreased expression of SPRY4 mRNA CTD PMID:23378141 fluoranthene multiple interactions ISO RGD:1313287 6480464 [1-methylanthracene co-treated with fluoranthene] results in increased expression of SPRY4 mRNA CTD PMID:28329830 folic acid multiple interactions ISO RGD:1313286 6480464 [Ethanol co-treated with Folic Acid] results in decreased expression of SPRY4 mRNA CTD PMID:23378141 folic acid decreases expression ISO RGD:1313287 6480464 Folic Acid results in decreased expression of SPRY4 mRNA CTD PMID:25629700 formaldehyde decreases expression ISO RGD:1313286 6480464 Formaldehyde results in decreased expression of SPRY4 mRNA CTD PMID:28937961 gentamycin decreases expression EXP 6480464 Gentamicins results in decreased expression of SPRY4 mRNA CTD PMID:22061828 gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of SPRY4 mRNA CTD PMID:33387578 glycidol decreases expression EXP 6480464 glycidol results in decreased expression of SPRY4 mRNA CTD PMID:24915197 hydrogen peroxide affects expression ISO RGD:1313286 6480464 Hydrogen Peroxide affects the expression of SPRY4 mRNA CTD PMID:23410634 hydroquinone increases expression ISO RGD:1313286 6480464 hydroquinone results in increased expression of SPRY4 mRNA CTD PMID:31256213 indometacin multiple interactions ISO RGD:1313286 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of SPRY4 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of SPRY4 mRNA CTD PMID:28628672 ivermectin decreases expression ISO RGD:1313286 6480464 Ivermectin results in decreased expression of SPRY4 protein CTD PMID:32959892 leflunomide increases expression ISO RGD:1313286 6480464 leflunomide results in increased expression of SPRY4 mRNA CTD PMID:28988120 Licochalcone B increases expression ISO RGD:1313286 6480464 licochalcone B results in increased expression of SPRY4 mRNA CTD PMID:33647349 manganese(II) chloride increases expression EXP 6480464 manganese chloride results in increased expression of SPRY4 mRNA CTD PMID:28801915 menadione affects expression ISO RGD:1313286 6480464 Vitamin K 3 affects the expression of SPRY4 mRNA CTD PMID:23410634 mercury dibromide multiple interactions ISO RGD:1313286 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPRY4 mRNA CTD PMID:27188386 methimazole increases expression EXP 6480464 Methimazole results in increased expression of SPRY4 mRNA CTD PMID:30047161 methotrexate affects expression ISO RGD:1313287 6480464 Methotrexate affects the expression of SPRY4 mRNA CTD PMID:18502557 methylarsonic acid multiple interactions ISO RGD:1313287 6480464 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPRY4 mRNA CTD PMID:34876320 methylisothiazolinone increases expression ISO RGD:1313286 6480464 2-methyl-4-isothiazolin-3-one results in increased expression of SPRY4 mRNA CTD PMID:31629900 methylmercury chloride increases expression ISO RGD:1313286 6480464 methylmercuric chloride results in increased expression of SPRY4 mRNA CTD PMID:28001369 mono(2-ethylhexyl) phthalate increases expression EXP 6480464 mono-(2-ethylhexyl)phthalate results in increased expression of SPRY4 mRNA CTD PMID:16809437 mono(2-ethylhexyl) phthalate increases expression ISO RGD:1313286 6480464 mono-(2-ethylhexyl)phthalate results in increased expression of SPRY4 mRNA CTD PMID:36695872 N-methyl-4-phenylpyridinium increases expression EXP 6480464 1-Methyl-4-phenylpyridinium results in increased expression of SPRY4 mRNA CTD PMID:28801915 N-Nitrosopyrrolidine increases expression ISO RGD:1313286 6480464 N-Nitrosopyrrolidine results in increased expression of SPRY4 mRNA CTD PMID:32234424 nitrofen decreases expression EXP 6480464 nitrofen results in decreased expression of SPRY4 mRNA CTD PMID:23982388 more ... ozone multiple interactions ISO RGD:1313286 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of SPRY4 mRNA more ... CTD PMID:32699268 ozone multiple interactions ISO RGD:1313287 6480464 [Air Pollutants results in increased abundance of Ozone] which results in increased expression of SPRY4 mRNA CTD PMID:34911549 paracetamol increases expression ISO RGD:1313286 6480464 Acetaminophen results in increased expression of SPRY4 mRNA CTD PMID:21420995 , PMID:29067470 PCB138 increases expression EXP 6480464 2 more ... CTD PMID:23829299 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:1313287 6480464 [perfluorooctane sulfonic acid co-treated with Pectins] results in decreased expression of SPRY4 mRNA CTD PMID:36331819 perfluorooctanoic acid increases expression ISO RGD:1313286 6480464 perfluorooctanoic acid results in increased expression of SPRY4 protein CTD PMID:26879310 phenylmercury acetate increases expression ISO RGD:1313286 6480464 Phenylmercuric Acetate results in increased expression of SPRY4 mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:1313286 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPRY4 mRNA CTD PMID:27188386 pirinixic acid decreases expression ISO RGD:1313287 6480464 pirinixic acid results in decreased expression of SPRY4 mRNA CTD PMID:23811191 potassium chromate multiple interactions ISO RGD:1313286 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SPRY4 mRNA CTD PMID:22079256 potassium chromate increases expression ISO RGD:1313286 6480464 potassium chromate(VI) results in increased expression of SPRY4 mRNA CTD PMID:22079256 pregnenolone 16alpha-carbonitrile increases expression EXP 6480464 Pregnenolone Carbonitrile results in increased expression of SPRY4 mRNA CTD PMID:30047161 progesterone increases expression ISO RGD:1313286 6480464 Progesterone results in increased expression of SPRY4 mRNA CTD PMID:18037150 progesterone multiple interactions ISO RGD:1313286 6480464 [Estradiol co-treated with Progesterone] results in decreased expression of SPRY4 mRNA CTD PMID:20660070 propiconazole decreases expression ISO RGD:1313287 6480464 propiconazole results in decreased expression of SPRY4 mRNA CTD PMID:21278054 rotenone increases expression ISO RGD:1313286 6480464 Rotenone results in increased expression of SPRY4 mRNA CTD PMID:29955902 S-(1,2-dichlorovinyl)-L-cysteine increases expression ISO RGD:1313286 6480464 S-(1, 2-dichlorovinyl)cysteine results in increased expression of SPRY4 mRNA CTD PMID:33725128 SB 431542 multiple interactions ISO RGD:1313286 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 silicon dioxide increases expression ISO RGD:1313286 6480464 Silicon Dioxide results in increased expression of SPRY4 mRNA CTD PMID:22300531 , PMID:25351596 silver atom increases expression ISO RGD:1313287 6480464 Silver results in increased expression of SPRY4 mRNA CTD PMID:27131904 silver atom increases expression ISO RGD:1313286 6480464 Silver results in increased expression of SPRY4 mRNA CTD PMID:26014281 silver(0) increases expression ISO RGD:1313287 6480464 Silver results in increased expression of SPRY4 mRNA CTD PMID:27131904 silver(0) increases expression ISO RGD:1313286 6480464 Silver results in increased expression of SPRY4 mRNA CTD PMID:26014281 sodium arsenate multiple interactions ISO RGD:1313287 6480464 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPRY4 mRNA CTD PMID:34876320 sodium arsenite multiple interactions ISO RGD:1313287 6480464 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPRY4 mRNA CTD PMID:34876320 sulfadimethoxine increases expression EXP 6480464 Sulfadimethoxine results in increased expression of SPRY4 mRNA CTD PMID:30047161 sulforaphane increases expression ISO RGD:1313286 6480464 sulforaphane results in increased expression of SPRY4 mRNA CTD PMID:31838189 tert-butyl hydroperoxide affects expression ISO RGD:1313286 6480464 tert-Butylhydroperoxide affects the expression of SPRY4 mRNA CTD PMID:23410634 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of SPRY4 mRNA CTD PMID:34492290 triclosan decreases expression ISO RGD:1313286 6480464 Triclosan results in decreased expression of SPRY4 mRNA CTD PMID:30510588 triptonide increases expression ISO RGD:1313287 6480464 triptonide results in increased expression of SPRY4 mRNA CTD PMID:33045310 troglitazone increases expression ISO RGD:1313287 6480464 troglitazone results in increased expression of SPRY4 mRNA CTD PMID:17569031 urethane increases expression ISO RGD:1313286 6480464 Urethane results in increased expression of SPRY4 mRNA CTD PMID:28818685 ursodeoxycholic acid affects expression ISO RGD:1313286 6480464 Ursodeoxycholic Acid affects the expression of SPRY4 mRNA CTD PMID:18422935 valproic acid decreases expression ISO RGD:1313287 6480464 Valproic Acid results in decreased expression of SPRY4 mRNA CTD PMID:21427059 valproic acid decreases expression EXP 6480464 Valproic Acid results in decreased expression of SPRY4 mRNA CTD PMID:29427782 valproic acid increases expression ISO RGD:1313286 6480464 Valproic Acid results in increased expression of SPRY4 mRNA CTD PMID:28001369 valproic acid affects expression ISO RGD:1313286 6480464 Valproic Acid affects the expression of SPRY4 mRNA CTD PMID:25979313 zinc atom multiple interactions ISO RGD:1313286 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of SPRY4 mRNA CTD PMID:18593933 zinc(0) multiple interactions ISO RGD:1313286 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of SPRY4 mRNA CTD PMID:18593933
